Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245479402> ?p ?o ?g. }
- W4245479402 endingPage "2556" @default.
- W4245479402 startingPage "2556" @default.
- W4245479402 abstract "Abstract Introduction In the last years genome wide profilings have identified recurrent Copy Number Alterations (CNA) in genes potentially involved in the pathogenesis of Acute Lymphoblastic Leukemia (ALL). These studies have identified deletions in B-cell development genes (IKZF1, EBF1, PAX5, TCF3, etc.), cell cycle regulation genes (CDKN2A/B, RB1, TP53, etc.), glucocorticoid resistance genes (BTG1, CREBBP) and growth factor receptors genes (CRLF2, CSF2RA, IL3RA) among others. Some of these CNA (i.e. IKZF1, CDKN2A, CRLF2) have been reported to have prognostic significance in several pediatric series but there are very few data regarding their impact in B-lineage adult ALL. Our aim was to analyze the frequency and prognostic significance of CNA in a series of 125 B-lineage adult ALL patients treated according to risk-adapted protocols from the Spanish PETHEMA Group. Methods Bone marrow or peripheral blood (with significant blast burden) samples from 125 B-lineage adult ALL patients enrolled in risk-adapted protocols from the PETHEMA Group were analyzed at diagnosis. MLPA assays (MRC-Holland) were performed for the following genes: IKZF1, IKZF2, IKZF3, EBF1, CDKN2A/B, PAX5, ETV6, BTG1, RB1, hsa-miR-31, X/Y PAR1 region genes (CRLF2, CSF2RA, IL3RA) and 14q32.33 region genes (IGH D, MTA1, KIAA0284). Fragment analysis was made by Genescan in an ABI-3130 sequencer (Applied Biosystems). Data normalization provided a value indicative of the presence or absence of CNA: 0-0.20 homozygous deletion, 0.21-0.70 heterozygous deletion, 0.71-1.30 normal, 1.31-1.70 heterozygous duplication and 1.71-2.20 homozygous duplication. Results The median age [range] was 40 [15-74] years, 71 (57%) males, median WBC count 12.11 x109/L [0.4-388]. Immunophenotype: pro-B 14 (11%), common 71 (58%), pre-B 26 (21%), mature-B 10 (8%), unavailable 2 (2%). Cytogenetics: normal 16 (13%), hyperdiploid 6 (5%), hypodiploid 2 (2%), t(9:22) 20 (16%), t(1;19) 8 (6%), 11q23/MLL 11 (9%), 8q24/C-MYC 7 (5%), complex 1 (1%), iAMP21 2 (2%), other translocations or deletions 31 (25%), no growth 20 (16%). CNA frequencies of the 125 patients are shown in the table. IKZF1 deletions were significantly associated with EBF1 deletions, high WBC count and Philadelphia (Ph) chromosome. In the IKZF1 deleted cohort whole gene deletions were as frequent as Ik6 isoforms (28% each). A high codeletion rate was detected in genes located in 9p (CDKN2A/B with PAX5, CDKN2A/B with hsa-miR-31 and PAX5 with hsa-miR-31). CDKN2A/B also showed concomitant deletions with ETV6 while PAX5 showed codeletions with BTG1. CDKN2A/B and PAX5 deleted patients had higher WBC counts than non-deleted individuals. Clinical follow-up data was available for 123 patients of the whole series and for the 105 patients of the Ph-negative cohort. Multivariate analysis showed that advanced age, BTG1 deletions and EBF1 deletions were negative prognostic factors for achieving Complete Remission (CR) and WBC count and IKZF1 deletions significantly reduced CR duration in both cohorts. Interestingly, there were significant differences in relapse rates between whole and partial gene IKZF1 deletions. IKZF1 haploinsufficient patients had a probability of CR duration at 3 years of 83% ± 30% vs. 6% ± 12% of partial gene deletion carriers. Advanced age and IKZF1 deletions were predictors for overall survival in the Ph-negative cohort and age>30 years, IKZF1 deletions and hsa-miR-31 deletions were associated with poor prognosis in the whole series. Conclusions In B-lineage adult ALL, deletions of IKZF1, EBF1, BTG1 or hsa-miR-31 are markers with prognostic significance in addition to age and WBC count. Patients with partial IKZF1 gene deletions have a significantly higher probability of relapse than those with whole gene loss. These genetic abnormalities could help to better define prognostic subgroups in adult patients with B-lineage ALL. Supported by the grants PI10/01417 and RD12-0036-0029 from Instituto Carlos III and a grant from the Spanish Society of Hematology and Hemotherapy (2012). Disclosures: No relevant conflicts of interest to declare." @default.
- W4245479402 created "2022-05-12" @default.
- W4245479402 creator A5002155891 @default.
- W4245479402 creator A5003682435 @default.
- W4245479402 creator A5006173909 @default.
- W4245479402 creator A5008564951 @default.
- W4245479402 creator A5012925920 @default.
- W4245479402 creator A5014791873 @default.
- W4245479402 creator A5017225753 @default.
- W4245479402 creator A5027357638 @default.
- W4245479402 creator A5027815550 @default.
- W4245479402 creator A5029238392 @default.
- W4245479402 creator A5029428458 @default.
- W4245479402 creator A5031467969 @default.
- W4245479402 creator A5033227605 @default.
- W4245479402 creator A5035896968 @default.
- W4245479402 creator A5042537187 @default.
- W4245479402 creator A5059594543 @default.
- W4245479402 creator A5062212455 @default.
- W4245479402 creator A5062307149 @default.
- W4245479402 creator A5065586970 @default.
- W4245479402 creator A5075950572 @default.
- W4245479402 creator A5077575417 @default.
- W4245479402 creator A5080835213 @default.
- W4245479402 creator A5084969602 @default.
- W4245479402 creator A5085825374 @default.
- W4245479402 creator A5087964828 @default.
- W4245479402 creator A5088243670 @default.
- W4245479402 creator A5089188528 @default.
- W4245479402 creator A5089228267 @default.
- W4245479402 creator A5089338383 @default.
- W4245479402 creator A5090786245 @default.
- W4245479402 date "2013-11-15" @default.
- W4245479402 modified "2023-10-18" @default.
- W4245479402 title "Prognostic Significance Of Copy Number Alterations In B-Lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled In Risk-Adapted Protocols From The Pethema Group" @default.
- W4245479402 doi "https://doi.org/10.1182/blood.v122.21.2556.2556" @default.
- W4245479402 hasPublicationYear "2013" @default.
- W4245479402 type Work @default.
- W4245479402 citedByCount "0" @default.
- W4245479402 crossrefType "journal-article" @default.
- W4245479402 hasAuthorship W4245479402A5002155891 @default.
- W4245479402 hasAuthorship W4245479402A5003682435 @default.
- W4245479402 hasAuthorship W4245479402A5006173909 @default.
- W4245479402 hasAuthorship W4245479402A5008564951 @default.
- W4245479402 hasAuthorship W4245479402A5012925920 @default.
- W4245479402 hasAuthorship W4245479402A5014791873 @default.
- W4245479402 hasAuthorship W4245479402A5017225753 @default.
- W4245479402 hasAuthorship W4245479402A5027357638 @default.
- W4245479402 hasAuthorship W4245479402A5027815550 @default.
- W4245479402 hasAuthorship W4245479402A5029238392 @default.
- W4245479402 hasAuthorship W4245479402A5029428458 @default.
- W4245479402 hasAuthorship W4245479402A5031467969 @default.
- W4245479402 hasAuthorship W4245479402A5033227605 @default.
- W4245479402 hasAuthorship W4245479402A5035896968 @default.
- W4245479402 hasAuthorship W4245479402A5042537187 @default.
- W4245479402 hasAuthorship W4245479402A5059594543 @default.
- W4245479402 hasAuthorship W4245479402A5062212455 @default.
- W4245479402 hasAuthorship W4245479402A5062307149 @default.
- W4245479402 hasAuthorship W4245479402A5065586970 @default.
- W4245479402 hasAuthorship W4245479402A5075950572 @default.
- W4245479402 hasAuthorship W4245479402A5077575417 @default.
- W4245479402 hasAuthorship W4245479402A5080835213 @default.
- W4245479402 hasAuthorship W4245479402A5084969602 @default.
- W4245479402 hasAuthorship W4245479402A5085825374 @default.
- W4245479402 hasAuthorship W4245479402A5087964828 @default.
- W4245479402 hasAuthorship W4245479402A5088243670 @default.
- W4245479402 hasAuthorship W4245479402A5089188528 @default.
- W4245479402 hasAuthorship W4245479402A5089228267 @default.
- W4245479402 hasAuthorship W4245479402A5089338383 @default.
- W4245479402 hasAuthorship W4245479402A5090786245 @default.
- W4245479402 hasConcept C104317684 @default.
- W4245479402 hasConcept C120599132 @default.
- W4245479402 hasConcept C126322002 @default.
- W4245479402 hasConcept C143998085 @default.
- W4245479402 hasConcept C203014093 @default.
- W4245479402 hasConcept C2780265364 @default.
- W4245479402 hasConcept C29447677 @default.
- W4245479402 hasConcept C36823959 @default.
- W4245479402 hasConcept C54355233 @default.
- W4245479402 hasConcept C63363279 @default.
- W4245479402 hasConcept C71924100 @default.
- W4245479402 hasConcept C86339819 @default.
- W4245479402 hasConcept C86803240 @default.
- W4245479402 hasConceptScore W4245479402C104317684 @default.
- W4245479402 hasConceptScore W4245479402C120599132 @default.
- W4245479402 hasConceptScore W4245479402C126322002 @default.
- W4245479402 hasConceptScore W4245479402C143998085 @default.
- W4245479402 hasConceptScore W4245479402C203014093 @default.
- W4245479402 hasConceptScore W4245479402C2780265364 @default.
- W4245479402 hasConceptScore W4245479402C29447677 @default.
- W4245479402 hasConceptScore W4245479402C36823959 @default.
- W4245479402 hasConceptScore W4245479402C54355233 @default.
- W4245479402 hasConceptScore W4245479402C63363279 @default.
- W4245479402 hasConceptScore W4245479402C71924100 @default.
- W4245479402 hasConceptScore W4245479402C86339819 @default.
- W4245479402 hasConceptScore W4245479402C86803240 @default.
- W4245479402 hasIssue "21" @default.
- W4245479402 hasLocation W42454794021 @default.